<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576376/" ref="ordinalpos=3470&amp;ncbi_uid=4625157&amp;link_uid=PMC3576376" image-link="/pmc/articles/PMC3576376/figure/pone-0056714-g004/" class="imagepopup">Figure 4. PCA <span class="highlight" style="background-color:">pathway</span> analysis of FLT3 ITD AML samples and healthy BMMb compared to FLT3 WT AML..  From: Functional <span class="highlight" style="background-color:">Pathway</span> Analysis Using SCNP of FLT3 Receptor <span class="highlight" style="background-color:">Pathway</span> Deregulation in AML Provides Prognostic Information Independent from Mutational Status. </a></div><br /><div class="p4l_captionBody">PCA analysis of FLT3L-induced signaling (PC 1) and AraC/Daunorubicin-induced apoptosis measured by cPARP (PC 2) in healthy BMMb (blue dots), FLT3 ITD (red dots) and FLT3 WT (green dots). Donors with low FLT3 ITD mutational load (&lt;40%) are indicated by arrows.</div></div>